Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Company Abbott Picks Singapore for Trial of New Cancer Drug (Singapore)

This article was originally published in PharmAsia News

Executive Summary

Abbott has recently completed successful Phase I trials of a new cancer drug in Singapore. The company has also announced the selection of Singapore as home to the drug's Phase II trials. Abbott Regional Director Cihangir Kosu says the company chose Singapore because of its "solid infrastructure, high quality of healthcare services, and the existence of outstanding clinical research." The Phase II trials of the drug will occur over a period of six to 18 months. The drug's effectiveness will be tested on between 40 and 60 end-stage cancer patients, as opposed to the 21 tested in the Phase I trials. The new drug works by blocking blood-flow to cancer tumors. Subjects in the Phase I trials saw reductions in tumor size, while avoiding many of the serious side effects associated with most chemotherapy treatments. (Click here for more

You may also be interested in...

Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts